MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

10X Genomics Inc (Class A)

Open

SectorHealthcare

12.06 4.06

Overview

Share price change

24h

Current

Min

11.52

Max

12.08

Key metrics

By Trading Economics

Income

69M

35M

Sales

18M

173M

EPS

0.28

Profit margin

19.975

Employees

1,306

EBITDA

86M

47M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+26.29% upside

Dividends

By Dow Jones

Next Earnings

28 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-111M

1.6B

Previous open

8

Previous close

12.06

News Sentiment

By Acuity

17%

83%

28 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

10X Genomics Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

7 Oct 2025, 16:58 UTC

Earnings

BMW Trims 2025 View, Citing Weaker Performance in China

7 Oct 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 Oct 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 Oct 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 Oct 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 Oct 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 Oct 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7 Oct 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 Oct 2025, 20:44 UTC

Hot Stocks

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 Oct 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 Oct 2025, 19:23 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 Oct 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 Oct 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 Oct 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 Oct 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 Oct 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 Oct 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 Oct 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 Oct 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 Oct 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 Oct 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 Oct 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 Oct 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Oct 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 Oct 2025, 14:52 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Comparison

Price change

10X Genomics Inc (Class A) Forecast

Price Target

By TipRanks

26.29% upside

12 Months Forecast

Average 14.65 USD  26.29%

High 17 USD

Low 11.5 USD

Based on 14 Wall Street analysts offering 12 month price targets for10X Genomics Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

5

Buy

9

Hold

0

Sell

Technical Score

By Trading Central

8.32 / 8.63Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

28 / 371 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat